
GLP-1 injections reshape the UK's obesity fight
GLP-1 weight‑loss injections, notably Wegovy and Mounjaro, are transforming obesity treatment in the UK and globally, delivering significant weight loss in trials and real life, but NHS access remains tightly restricted by cost under NICE criteria, prompting concerns about inequality and a growing private market; with more than 50 obesity drugs in trials and new forms like tablets on the horizon, experts expect broader options that could reduce surgery needs while underscoring the importance of addressing underlying causes.







